Craig K, Gomez H F, McManus J L, Bania T C
Department of Emergency Medicine of St. Luke's-Roosevelt Hospital, New York, New York, USA.
J Emerg Med. 2000 Jan;18(1):65-70. doi: 10.1016/s0736-4679(99)00163-8.
We report a case of gamma-hydroxybutyrate (GHB) withdrawal resulting in severe agitation, mental status changes, elevated blood pressure, and tachycardia hours after stopping chronic use of GHB. The patient admitted to substantial GHB abuse on a daily basis for 2.5 years. Previous attempts at cessation reportedly resulted in diaphoresis, tremors, and agitation. The patient's symptoms, negative polypharmacy history, and negative urine and blood toxicological analysis for alcohol, benzodiazepines, sedative-hypnotics, or other substances suggested the diagnosis of GHB withdrawal. Later analysis of a patient drug sample confirmed the presence of GHB. The patient required 507 mg of lorazepam and 120 mg of diazepam over 90 h to control agitation. This is one of the few reported cases of GHB withdrawal and one of the most severe. Given the increasing use of GHB, more cases of severe GHB withdrawal should be anticipated.
我们报告了一例γ-羟基丁酸（GHB）戒断病例，该患者在长期使用GHB后停药数小时出现严重躁动、精神状态改变、血压升高和心动过速。患者承认每天大量滥用GHB达2.5年。据报道，之前尝试停药时出现了出汗、震颤和躁动。患者的症状、无多种药物合用史以及酒精、苯二氮䓬类药物、镇静催眠药或其他物质的尿液和血液毒理学分析结果均为阴性，提示为GHB戒断诊断。后来对患者的药物样本进行分析，证实存在GHB。患者在90小时内需要507毫克劳拉西泮和120毫克地西泮来控制躁动。这是少数几例报道的GHB戒断病例之一，也是最严重的病例之一。鉴于GHB的使用日益增加，预计会出现更多严重的GHB戒断病例。
